Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Says China Accepts Filing of Phase I GBM Trial for Review

publication date: May 25, 2021

Hangzhou's Ascletis Pharma reported that China has accepted for review the company's filing for a clinical trial of a brain cancer treatment. Ascletis intends to test a combination of ASC40 and bevacizumab in patients with recurrent glioblastoma (rGBM). ASC40 is an oral small molecule inhibitor of fatty acid synthase (FASN), a protein that regulates lipid metabolism and is present in many cancers. In 2019, Ascletis acquired China rights to the candidate from San Francisco's 3-V Biosciences for NASH. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here